Synta Pharmaceuticals Corp. said it appointed Vojo Vukovic as vice president of clinical research. Vukovic will be the Synta medical lead for the company's most advanced oncology product candidate, elesclomol, and will support the implementation of a broad development strategy for elesclomol.

Vojo Vukovic, with over 15 years of experience in oncology drug development, joins Synta from Pfizer Inc., where he was Global Medical Lead for Sutent and axitinib in a number of cancer indications.

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.